Azenta, Inc. has signed a deal with Elegen Corp. and bought SynPlexity Inc. to boost its gene synthesis abilities.

Oct 30, 2026, 8:08 AM ETDealRead the original at SEC EDGAR

Good for AZTA

Azenta gains a royalty-free license to sell certain gene-synthesis products worldwide and adds SynPlexity's DNA assembly technology to GENEWIZ. The possible $32 million to $71 million spend and 5-year exclusive term are outweighed by the added capabilities.

AZTA · Azenta, Inc.

AI read · Good for AZTA

The AI's read

The added rights give Azenta more ways to make and sell gene-synthesis products and build regional production. SynPlexity adds DNA assembly tools and expertise to GENEWIZ. The deals may require $32 million to $71 million in spending, and the license may become non-exclusive after 5 years without a paid conversion. The added capabilities support growth despite those costs and limits.

Get alerts for AZTA

Follow Azenta, Inc. (AZTA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AZTA

Free on the App Store and Google Play, or on the web.